This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Pathological process

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The whole progression of Perthe's disease takes between 2 and 4 years.

The aetiology is unknown but the following factors may be important:

  • repetitive microtrauma
    • the disease is frequently seen in hyperactive children where repetitive microtrauma results in small fractures of the immature femoral head (1)
  • vascular insufficiency (1)
  • growth plate disruption
  • infection and transient synovitis
  • hypercoagulability (2)
  • a slipped capital femoral epiphysis
  • congenital dislocation of the hip

Firstly there is bone death - this appears normal on a radiograph, but is seen on MRI - in association with loss of vascularisation.

Fragmentation follows; the epiphysis may flatten as a result of poor repair of microfractures.

Lastly there is revascularisation, repair and remodelling of the femoral head.

Note that this process is entirely different from the irreversible death of the femoral head in adult avascular necrosis.

Reference:

  1. Nelitz M, Lippacher S, Krauspe R, Reichel H. Perthes Disease Current Principles of Diagnosis and Treatment Dtsch Arztebl Int. 2009; 106(31-32): 517–523.
  2. Kim HK. Legg-Calve-Perthes disease. J Am Acad Orthop Surg.2010;18(11):676-86

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.